Volume 96 Issue 7 | p. 12 | Concentrates
Issue Date: February 12, 2018

Syndesi launches as spin-off from UCB

Department: Business
Keywords: Neuroscience, drug discovery, Syndesi

Syndesi Therapeutics has launched with about $21 million in funding from investors including UCB and Johnson & Johnson. Based at J&J’s JLINX incubator in Beerse, Belgium, Syndesi will develop small molecules licensed from UCB that modulate the synaptic vesicle protein SV2A. UCB markets the SV2A modulator levetiracetam as an epilepsy treatment. The compounds that went to Syndesi are not antiepileptic but have what Syndesi calls procognitive properties that could treat neurological disorders such as Alzheimer’s disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment